Exact Sciences Corp. announced the launch of Cologuard Plus??, the most accurate noninvasive colorectal cancer screening (CRC) test reported in studies to date. FDA-approved for average-risk patients 45+ and covered by Medicare, the Cologuard Plus test detects 95% of colorectal cancers at 94% specificity in the U.S. screening population.1+ This performance means fewer unnecessary follow-up colonoscopies--up to a 40% reduction compared to the original Cologuard®?
test2--and greater confidence in results. Building on the trust and success of Cologuard--used for more than 19 million screenings over the past decade--Cologuard Plus delivers even greater performance while maintaining the convenience of at-home collection. Backed by pivotal data from the 20,000+ person BLUE-C study published in the New England Journal of Medicine, the Cologuard plus test sets a new standard for noninvasive CRC screening: Unmatched Noninvasive CRC Accuracy: 95% sensitivity for CRC detection, versus 71% sensitivity with fecal immunochemical test (FIT).
Fewer false Positives: 40% reduction compared to the Original Cologuard test. High Precancerous Lesion Detection: 43% sensitivity for advanced precancerous lesions and 74% sensitivity for high-grade dysplasia--the type of precancerous growths most likely to become cancer. Greater Confidence in Negative Results: A negative Cologuard Plus result means a 99.98% chance the patient does not have colorectal cancer--offering peace of mind to both patients and clinicians.
Access & Coverage: Covered by Medicare and included in the U.S. Preventive Services Taskforce (USPSTF) guidelines as a recommended stool-based screening option. Recognized for Quality Care: Satisfies three years of colorectal cancer screening quality measure credit, helping health care professionals meet screening goals while improving patient outcomes. Effective screening depends on patient adherence, and Cologuard Plus is designed to remove barriers to testing.
A large national sample of Cologuard orders shows that 71% of patients complete their test within an average of 28 days, significantly outperforming adherence rates seen in separate meta-analyses for FIT (42%) or colonoscopy referrals (38%). Follow-up adherence is also strong--79% of patients who receive a positive Cologuard result complete a colonoscopy, and 83% of patients complete repeat screening three years later. These adherence rates are critical in detecting cancer early and ensuring patients get the care they need.
Like the original Cologuardtest, the CologuardPlus test is shipped directly to a patient's home and integrates with the ExactNexus?? technology platform. This platform simplifies ordering, result delivery, and patient navigation--a feature proven to improve test completion rates.
As Exact Sciences works to expand patient access to the Cologuard Plus testing, the original Cologuard test will remain available. nationwide, more than 96% of patients aged 45 and older have no out-of-pocket costs for screening with the Cologuard test. Based on relative comparison to published reports; not direct evidence from head-to-head comparisons with all other screening tests.
Effect of colonoscopy outreach vs fecal immunochemical test outreach on colorectal cancer screening completion: a randomized clinical trial. The Cologuard test revolutionized CRC screening by detecting specific DNA markers and blood in stool associated with cancer and precancer, allowing patients to complete the test at home without special preparation or time off. Building on this success, the FDA-approved Cologuard Plus test raises the performance bar even further and features novel biomarkers, improved laboratory processes, and enhanced sample stability.
The Cologuard Plus test is expected to reduce false positives by more than 40% compared to the original CologUard test is expected to reduce false false positives by more than 40%. The Cologuard Plus testing is expected to reduce false positives By more than 40% compared to The Cologuard Plus tests are expected to the original Cologuards test is expected to the original CologU.
